Stocks of Transmedics Group Inc (NASDAQ:TMDX) traded higher last session on Wall Street, down -5.16% to $68.81.
TMDX stock price is now -8.20% away from the 50-day moving average and -42.73% away from the 200-day moving average. The market capitalization of the company currently stands at $2.31B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $116 to $75, JP Morgan Downgraded its rating from Overweight to Neutral for Transmedics Group Inc (NASDAQ: TMDX). , while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Khayal Tamer I, Chief Commercial Officer sold 1,083 shares of the company’s stock on Jan 07 ’25. The stock was sold for $86,694 at an average price of $80.05. Upon completion of the transaction, the Chief Commercial Officer now directly owns 20,843 shares in the company, valued at $1.43 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 02 ’24, Chief Commercial Officer Khayal Tamer I sold 1,084 shares of the business’s stock. A total of $93,658 was realized by selling the stock at an average price of $86.40. This leaves the insider owning 20,843 shares of the company worth $1.43 million. A total of 3.39% of the company’s stock is owned by insiders.
During the past 12 months, Transmedics Group Inc has had a low of $58.27 and a high of $177.37. As of last week, the company has a debt-to-equity ratio of 2.47, a current ratio of 8.20, and a quick ratio of 7.33. The fifty day moving average price for TMDX is $74.9533 and a two-hundred day moving average price translates $120.1469 for the stock.
The latest earnings results from Transmedics Group Inc (NASDAQ: TMDX) was released for 2024-09-30. The net profit margin was 8.14% and return on equity was 19.41% for TMDX. The company reported revenue of $108.76 million for the quarter, compared to $66.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 63.72 percent.
